Plasma protein binding of perazine and amitriptyline in psychiatric patients

The free fraction of amitriptyline (AT), measured by equilibrium dialysis in plasma from 29 AT-treated depressed patients, was 5.4-9.8% (mean 7.7%), which was the same as the values in 26 healthy controls (4.9-9.6%, mean 7.6%). The plasma levels of lipoproteins, as reflected by total cholesterol, an...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1982-01, Vol.22 (4), p.367-373
Main Authors: Brinkschulte, M, Gaertner, H J, Schied, H W, Breyer-Pfaff, U
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Amitriptyline - blood
Amitriptyline - therapeutic use
Antipsychotic Agents - blood
Blood Proteins - metabolism
Depressive Disorder - blood
Depressive Disorder - drug therapy
Female
Humans
Lipoproteins - blood
Male
Middle Aged
Perazine - blood
Perazine - therapeutic use
Protein Binding
Schizophrenia - blood
Schizophrenia - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The free fraction of amitriptyline (AT), measured by equilibrium dialysis in plasma from 29 AT-treated depressed patients, was 5.4-9.8% (mean 7.7%), which was the same as the values in 26 healthy controls (4.9-9.6%, mean 7.6%). The plasma levels of lipoproteins, as reflected by total cholesterol, and of alpha 1-acid glycoprotein (alpha 1-AGP) did not differ between the two groups. the free fraction of AT in both exhibited a significant negative correlation with the concentrations of those two proteins. The unbound fraction of perazine (PER) was the same (3.1-5.9%, mean 4.4%) in plasma from 22 schizophrenic patients and from 24 healthy volunteers (2.9-6.0%, mean 4.5%). However, in patient plasma alpha 1-AGP was significantly higher (mean 1.07 vs 0.81 mg/ml) and total cholesterol tended to be lower (mean 173 vs 201 mg/100 ml) than in plasma from normals. In consequence, the free fraction of PER was negatively correlated with the alpha 1-AGP concentration in plasma from patients and with the cholesterol level in plasma from control subjects; the other correlations were not significant. In 7 patients, the alpha 1-AGP level was normal prior to Per treatment. Serial blood samples from 6 patients revealed a consistent elevation of alpha 1-AGP above its pretreatment level during 4 weeks of PER administration in 5 of the subjects and a transient increase in one other. while low lipoprotein levels in schizophrenics seem to be a disease-related trait, the increase of alpha 1-AGP may be a drug effect.
ISSN:0031-6970
1432-1041
DOI:10.1007/BF00548407